VOT Receives FDA Approval
VOT announces it received 510K approval from the FDA for a new uni-compartmental knee implant called "SoloTM Partial Knee System." The major advantage of the Solo Partial Knee is that the device can be surgically implanted using an arthroscopic assisted technique through a single, 25 mm (1 inch) opening which dramatically reduces the incision size and soft tissue trauma to the patients compared to conventional partial knee replacements. The procedure also utilizes bone sparing resection techniques which opens the procedure up to much younger patients.
"This is an important milestone for our young company," says Hans Stover, President & CEO of VOT Solutions. "We believe this product will provide a great solution to patients who suffer from osteoarthritis, but who are not ready for a total knee replacement."
Knee arthritis afflicts millions of people and each year approximately 660,000 knee joint replacements are implanted in the US alone. Annual growth rates over the last decade average greater than 10% and the market is expected to exceed a million surgeries by 2010. The number of knee replacement candidates who decline surgery (i.e. patients in these treatment gaps who are foregoing surgical treatment) is undocumented, but projected to be quite large, given that over 21 million people in the US suffer from osteoarthritis.
VOT Solutions is an orthopedic medical device company located in Warsaw, IN and is focused on the design and development of innovative knee arthroscopic and arthroplasty surgical devices.
For more information about the company please contact Tom Carter, Vice President of Sales & Marketing at 438 E. 200 N, Warsaw, IN 46582, phone at 574-269-4103, ext 224.